Svetlana Shikanova

Svetlana Shikanova

Auto-generated profile, based on publicly available information

Svetlana Shikanova

Department of Obstetrics and Gynecology №1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
IIbrahim Abdelazim
Ibrahim Abdelazim
SSSvetlana Shikanova
Svetlana Shikanova
GZGulmira Zhurabekova
Gulmira Zhurabekova
KSKanshayim Jarasovna Sakieva
Kanshayim Jarasovna Sakieva
BKBakyt Karimova
Bakyt Karimova
MSMukhit Sarsembayev
Mukhit Sarsembayev

22 October 2018 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
IIbrahim Abdelazim
Ibrahim Abdelazim
BNBassam Nusair
Bassam Nusair
SSShikanova Svetlana
Shikanova Svetlana
GZGulmira Zhurabekova
Gulmira Zhurabekova

21 October 2020 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Open access
PDF file
IIbrahim Abdelazim
Ibrahim Abdelazim
SSSvetlana Shikanova
Svetlana Shikanova
BKBakyt Karimova
Bakyt Karimova
MSMukhit Sarsembayev
Mukhit Sarsembayev
GMGulmira Mukhambetalyeva
Gulmira Mukhambetalyeva
MBMariya Bekzhanova
Mariya Bekzhanova
Failure to identify women with ruptured fetal membranes (RFM) is associated with subsequent infectious morbidity. To evaluate the diagnostic accuracy of AmnioQuick Duo in the detection of RFM, One hundred and twenty-five women (125) in the preterm premature rupture of fetal membranes/premature rupture of fetal membranes (PPRFM/PRFM) group were compared to one hundred and twenty women (120) controls in this study. On admission, after thorough history, the participants were examined by trans-abdominal sonography for evaluation of the amniotic fluid index (AFI), followed by sterile vaginal speculum examination to detect leaking amniotic fluid from the cervix, and for collection of samples for nitrazine, fern, and AmnioQuick Duo tests. The RFM were confirmed at delivery and compared using the recorded data of admission to evaluate the diagnostic accuracy of the AmnioQuick Duo in the detection of RFM (primary outcome). The AmnioQuick Duo test had 97.6% sensitivity, 98.3% specificity, 98.4% positive predictive value (PPV), 97.5% negative predictive value (NPV), and 97.95% overall accuracy in the detection of PPRFM/PRFM. The Nitrazine test had 64.8% sensitivity, 64.2% specificity, 65.3% PPV, 63.6% NPV, and overall accuracy 64.5% in the detection of PPRFM/PRFM. Fern test had 63.2% sensitivity, 59.2% specificity, 61.7% PPV, 60.7% NPV, and 61.2% overall accuracy in the detection of PPRFM/PRFM. The combined IGFBP-1/AFP (AmnioQuick Duo) test is an accurate bedside test with 97.6% sensitivity, 98.3% specificity, 98.4% PPV, 97.5% NPV, and 97.95% overall accuracy in the detection of PPRFM/PRFM. The sensitivity, specificity, PPV, NPV, and the overall accuracy of the AmnioQuick Duo were significantly higher than in the standard diagnostic nitrazine or fern tests in the detection of RFM.

9 March 2019 in The Journal of Obstetrics and Gynecology of India
Verified
Journal Article
Closed access
PDF file
IIbrahim Abdelazim
Ibrahim Abdelazim
SSSvetlana Shikanova
Svetlana Shikanova
BKBakyt Karimova
Bakyt Karimova
MSMukhit Sarsembayev
Mukhit Sarsembayev
TSTatyana Starchenko
Tatyana Starchenko
GMGulmira Mukhambetalyeva
Gulmira Mukhambetalyeva

8 April 2021 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
IIbrahim Abdelazim
Ibrahim Abdelazim
SSSvetlana Shikanova
Svetlana Shikanova
BKBakyt Karimova
Bakyt Karimova
MSMukhit Sarsembayev
Mukhit Sarsembayev
GMGulmira Mukhambetalyeva
Gulmira Mukhambetalyeva

1 January 2021 in Gynecology Obstetrics & Reproductive Medicine
Verified
Journal Article
Open access
PDF file
IIbrahim Abdelazim
Ibrahim Abdelazim
MAMohannad AbuFaza
Mohannad AbuFaza
SASoud M. Al-Ajmi
Soud M. Al-Ajmi
OAOsama O. Amer
Osama O. Amer
SSSvetlana Shikanova
Svetlana Shikanova
BKBakyt Karimova
Bakyt Karimova
OBJECTIVES: This study designed to compare the efficacy, and tolerability of heme-iron OptiFer® to ferrous fumarate in the treatment of iron deficiency anemia during pregnancy. STUDY DESIGN: Two hundred and thirty-four (234) women with iron deficiency anemia during pregnancy were included in this study; 121 women in the heme-iron OptiFer® group, and 113 women in the ferrous fumarate group. Women in the heme-iron OptiFer® group received OptiFer® tablets twice daily for ≥3 months then once daily as a maintenance dose. Women in the ferrous fumarate group received 350 mg oral ferrous fumarate once daily for ≥3 months. The pre-treatment ferritin, hemoglobin, red blood cells-mean corpuscular volume, and red blood cells-mean corpuscular hemoglobin were compared by the post-treatment values in the two studies. RESULTS: The post-treatment hemoglobin and ferritin were significantly high in the heme-iron OptiFer® group (11.2±7.1 gm/dL and 112.8±54.8 ug/l, respectively) compared to the ferrous fumarate group (10.9 ±5.1 and 89.9±43.3, respectively; p=0.0002 and p=0.006; respectively). The post-treatment red blood cells-mean corpuscular volume and red blood cells-mean corpuscular hemoglobin were significantly high in the heme-iron OptiFer® group (92.0±4.1 fl and 31.9±6.2 pg, respectively) compared to the ferrous fumarate group (87.7±2.9 and 28.5±4.7, respectively; p=0.0001 and p=0.001, respectively). The rates of poor compliance and gastrointestinal intolerance were significantly high in the ferrous fumarate group compared to the heme-iron OptiFer® group (12.4% and 19.5%, respectively versus 3.3% and 2.5%, respectively), (p=0.01 and p=0.0001, respectively). CONCLUSION: Heme-iron OptiFer® is an effective therapeutic option for the treatment of iron deficiency anemia during pregnancy with low side effects. heme-iron OptiFer® can be used in women who have low compliance, and/or gastrointestinal intolerance to conventional iron salts.